Economics of the antithymocyte globulins Thymoglobulin® and Atgam® in the treatment of acute renal transplant rejection

PharmacoEconomics

Volumn 17, Issue 3, 2000, Pages 287-293

  Schnitzler, Mark A ^a,d   Woodward, Robert S ^a   Lowell, Jeffrey A ^a   Amir, Leah ^b   Schroeder, Timothy J ^c   Singer, Gary G ^d   Brennan, Daniel C ^a,d  

^a WASHINGTON UNIVERSITY   (United States)

^b Inst for Qual Resource Management   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTICENTER STUDY; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0034001163     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017030-00006     Document Type: Article

References (11)

1. 1. Benvenisty AI, Tannenbaum GA, Cohen DJ, et al. Use of antithymocyte globulin and cyclosporine to treat steroid-resistant rejection episodes in renal transplant recipients. Transplant Proc 1987; 19: 1889-91
2. 2. O'Donaghue DJ, Johnson RW, Mallick NP, et al. Rabbit antithymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. Transplant Proc 1989; 21: 1736-7
3. 3. Filo RS, Smith EJ, Leapman SB. Reversal of acute cadaveric renal allograft rejection with adjunctive ATG therapy. Transplant Proc 1981; 13: 482-90
4. 4. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blinded, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes following renal transplantation. Transplantation 1998; 66 (1): 29-37
5. 5. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411
6. 6. Bonk RJ, McGhan WF. Pharmacoeconomic evaluation to assist prescription drug pricing: a US perspective on an international issue. Pharmacoeconomics 1993; 4 (2): 73-6
7. 7. Reekie WD, Buxton MJ. Cost-effectiveness as a guide to pricing a new pharmaceutical product. S Afr Med J 1994; 84: 421-3
8. 8. Brennan DC, Schnitzler MA, Baty JD, et al. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients. Pharmacoeconomics 1997; 11 (3): 237-45.
9. 9. Drug topics red book, Montvale (NJ): Medical Economics Company Inc., 1996
10. 10. United States Renal Data System. The economic cost of ESRD, vascular access procedures, and Medicare spending for alternative modalities of treatment (chapter 10). In: The 1997 annual data report. Ann Arbor (MI): United States Renal Data System, 1998: 143-62
11. 11. Eggers PW, Kucken LE. Cost issues in transplantation. Surg Clin North Am 1994; 74 (5): 1259-67